QIAGEN reports equity-based award settlement for supervisory board member

Qiagen ( (QGEN) ) has provided an announcement.

QIAGEN N.V. disclosed a managers’ transaction involving supervisory board member Toralf Haag, in line with EU market abuse regulations governing insider dealings. The transaction concerns the release and settlement of equity-based compensation rather than an open-market share purchase or sale.

Haag received 4,490 restricted stock units granted in February 2021, which vested on February 26, 2026, at a closing share price of $49.08. Following net share settlement to cover taxes and related expenses, he ultimately received 2,256 common shares outside a trading venue, underscoring ongoing alignment of management incentives with shareholder interests through stock-based remuneration programs.

The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

QIAGEN N.V. is a Netherlands-based life sciences company that develops and supplies sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on several European exchanges as well as on the NYSE and Swiss markets, reflecting a broad international investor base.

Average Trading Volume: 2,173,009

Technical Sentiment Signal: Strong Buy

Current Market Cap: $10.1B

For an in-depth examination of QGEN stock, go to TipRanks’ Overview page.